NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ProQR Therapeutics N.V. (PRQR) Stock Analysis

ProQR Therapeutics N.V. (PRQR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PRQR

$1.37

−$0.01 (−0.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRQR with… →

PRQR Key Statistics

As of Oct 21, 2026
Trading
Open
$1.38
Previous Close
$1.38
Day's Range
1.36–1.42
52-Week Range
1.30–3.00
Volume
647.87K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.20
Valuation
Market Cap
$193.33M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.45
Financials (FY)
Revenue (FY)
$15.91M−15.86%
Net Income (FY)
−$42.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
−228.18%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
141.12M
1-Year Return
−53.56%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
805.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PRQR closed at $1.37, −53.56% over 1 year.

ProQR Therapeutics N.V. (PRQR) has a market capitalization of $193.33M.

In fiscal 2025, PRQR reported revenue of $15.91M.

PRQR Stock Return by Calendar Year

ProQR Therapeutics N.V. (PRQR) 10-year return: what $10,000 became

1 year
$10,000 $4,644
−53.56%
5 years
$10,000 $1,789
−82.11%
10 years
$10,000 $2,141
−78.59%

If you had invested $10,000 in ProQR Therapeutics N.V. (PRQR) 10 years ago, at the close on October 21, 2016, it would have been worth $2,141 at the close on October 21, 2026: −78.59% in total, −14.29% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.18%
2025−23.77%
2024+33.84%
2023−46.49%
2022−53.81%
2021+90.71%
2020−57.62%
2019−37.20%
2018+389.30%
2017−34.18%
2016 (partial year)−2.00%

As of October 21, 2026.

PRQR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$15.91M−$42.18M−265.2%
2024$18.91M−$27.76M−146.9%
2023$6.51M−$28.12M−431.7%
2022$3.59M−$64.42M−1,792.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$15.91M—−$43.45M−$42.18M−265.2%
2024$18.91M—−$30.47M−$27.76M−146.9%
2023$6.51M—−$34.79M−$28.12M−431.7%
2022$3.59M—−$65.16M−$64.42M−1,792.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRQR Valuation vs Biotechnology Median

Median of 608 stocks
MetricPRQRBiotechnology medianvs median
P/S ratio10.4913.3021% below
Profit margin−228.18%−38.31%189.9 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ProQR Therapeutics N.V. (PRQR) is capitalised at $193.33M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 186.

The most recent close on file for PRQR is $1.37, dated October 21, 2026. That is −$0.01 (−0.72%) against the previous close. The 52-week range on file runs from $1.30 to $3.00. The latest close sits 5.38% above that 52-week low.

Financial Health

In fiscal 2025, ProQR Therapeutics N.V. reported revenue of $15.91M. Against the prior fiscal year total of $18.91M, that is a change of −15.86%. The same year closed with a net loss of $42.18M. The reported profit margin is −228.18%. That is 189.9 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −0.45.

Across the 4 fiscal years on file, revenue moves from $3.59M in 2022 to $15.91M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 10.49. On price-to-sales that is 21.09% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.2. Daily returns over the trailing 10 years annualize to a volatility of 96.56%. Over the trailing twelve months the total return is −53.56%. Across 10 years the annualized return works out at −14.29%.

Growth & Income

The record shows no dividend for PRQR.

The strongest complete calendar year on file is 2018 at +389.30%; the weakest is 2020 at −57.62%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −32.18%.

Peer Comparison

ProQR Therapeutics N.V. (PRQR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ProQR Therapeutics N.V. PRQR $193.33M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ProQR Therapeutics N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Visit website →